NCT04786067 is a Phase 4 clinical trial of Belatacept in Kidney Transplant Immunosuppression, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT04786067?

NCT04786067 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT04786067?

Interventions in NCT04786067: Belatacept.

What condition does NCT04786067 study?

NCT04786067 studies Kidney Transplant Immunosuppression.

Is NCT04786067 still recruiting?

NCT04786067 is currently completed. Last updated 12 January 2026.

Last reviewed 2026-01-12 · How we verify

NCT04786067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

Completed Phase 4 Last updated 12 January 2026

What this trial tests

Phase 4 trial testing Belatacept in Kidney Transplant Immunosuppression in 25 participants. Completed in 30 July 2025.

Timeline

28 July 2021

Primary endpoint
10 July 2025

30 July 2025

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	28 July 2021
Primary completion	10 July 2025
Estimated completion	30 July 2025
Sites	1 location across United States

Drugs / interventions tested

Belatacept (BELATACEPT) — full drug profile →

Conditions studied

Kidney Transplant Immunosuppression — all drugs for Kidney Transplant Immunosuppression →

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Kidney Transplant Immunosuppression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune quiescence. The primary objective will be to determine if donor derived-cell free DNA (AlloSure) can be utilized to facilitate Belatacept monotherapy, and to determine if Belatacept is safe and effective as immunosuppression in kidney transplant recipients. The secondary objective is to determine the utility of AlloMap as a predictor of immune quiescence and tolerance of immunosuppressive de-escalation to Belatacept monotherapy, and to evaluate the performance of iBox in predicting adverse outcomes in patients transitioned to Belatacept monotherapy

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Current State of Donor-Derived Cell-Free DNA Use in Allograft Monitoring in Kidney Transplantation.
Kueht ML, Dongur LP, Cusick M, Stevenson HL, et al · · 2022 · cited 9× · PMID 36294839 · DOI 10.3390/jpm12101700
Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study.
Osmanodja B, Akifova A, Oellerich M, Beck J, et al · · 2023 · cited 8× · PMID 36983437 · DOI 10.3390/jcm12062437
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation.
Raszeja-Wyszomirska J, Macech M, Kolanowska M, Krawczyk M, et al · · 2023 · cited 6× · PMID 37580899 · DOI 10.12659/aot.939750
Donor-derived cell-free DNA and its utility in kidney transplantation: A myth or a reality.
Khalil MAM, Sadagah NM, Mahmood HHK, Altom AA, et al · · 2025 · PMID 41479839 · DOI 10.5527/wjn.v14.i4.109099
Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival.
Kim GR, Nam KH, Choi JM. · · 2024 · PMID 39690903 · DOI 10.4285/ctr.24.0057

Verify or expand the search:

Other trials of Belatacept

Trials testing the same drug.

NCT06918990 — Treatment of Antibody-Mediated Rejection (ABMR) With CarBel · Phase 2 · not yet recruiting
NCT06291077 — Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BEL · Phase 4 · not yet recruiting
NCT06478017 — Belatacept in Heart Transplantation · Phase 2 · recruiting
NCT06055608 — Advancing Transplantation Outcomes in Children · Phase 2 · recruiting
NCT06307808 — Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination · unknown

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04786067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04786067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing